Q-omics provides the consensus-scored FGF12-AS1 profile across patient tissues and cancer cell-line models. FGF12-AS1 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, FGF12-AS1 is differentially expressed in 1, with the highest sampling consensus in LUSC. Additionally, FGF12-AS1 RNA expression shows 15,113 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight CHOL, LUSC, and HNSC as cancer lineages where FGF12-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FGF12-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FGF12-AS1 survival associations across molecular data types. FGF12-AS1 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FGF12-AS1 RNA expression–survival associations across cancer types. High FGF12-AS1 expression shows unfavorable associations in CHOL, PAAD, KIRC, ACC, BLCA and THCA. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CHOL as the clearest survival context for FGF12-AS1 RNA expression.
This table summarizes FGF12-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for FGF12-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FGF12-AS1 shows higher tumor expression in LUSC. The LUSC box plot shows higher FGF12-AS1 RNA expression in tumor versus normal tissue (log2 FC = +0.035, t-test p = .022).
This table shows molecular features associated with FGF12-AS1 in patient tissues and cancer cell lines. In patient samples, FGF12-AS1 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
